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AbstrAct
Objective Gastro-oesophageal reflux disease (GORD) is 
a common comorbidity among patients with rheumatoid 
arthritis (RA). While GORD has been attributed to the 
antirheumatic medications, no studies of human cohorts 
have investigated a link between GORD and RA. This 
study investigates whether GORD is associated with a 
subsequent RA diagnosis over a 5-year follow-up using a 
population-based dataset.
setting Taiwan
Participants We used data from the Taiwan Longitudinal 
Health Insurance Database. The study group consisted of 
13 645 patients with an ambulatory claim showing a GORD 
diagnosis. We used propensity score matching to select 
13 645 comparison patients (one per study patient with 
GORD).
Intervention We tracked each patient’s claims over a 
5-year period to identify those who subsequently received 
a diagnosis of RA. Cox proportional hazard (PH) regression 
modelling was used for analysis.
results Over 5-year follow-up, RA incidence rate per 
1000 person-years was 2.81 among patients with GORD 
and 0.84 among the comparison group. Cox PH modelling 
showed that GORD was independently associated with 
a 2.84-fold increased risk of RA (95% CI 2.09 to 3.85) 
over 5-year follow-up, after adjusting for the number of 
ambulatory care visits within the year following the index 
date (to mitigate surveillance bias).
conclusions We observed that GORD might associate 
with subsequent RA occurrence. Because current 
treatment guidelines for RA emphasise early diagnosis 
and prompt treatment, the observed association between 
GORD and RA may help acquaint clinicians to patients with 
GORD with higher RA risk and facilitate early diagnosis and 
treatment.
IntrOductIOn
Rheumatoid arthritis (RA) is one of the 
most widely prevalent chronic inflamma-
tory diseases. Although predominantly 
involving the joints, RA is recognised as 
a systemic condition with extra-articular 
manifestations.1 RA affects about 0.5%–1% 
of the adult population and is associated with 
progressive worsening of joint function and 
increased morbidity and mortality.2–4 Due 
to musculoskeletal deficits, patients with RA 
may experience cumulative comorbidity risks, 
deteriorating physical function, declining 
quality of life and substantial medical and 
socioeconomic burdens.5 6 Upper gastroin-
testinal (GI) disease is a recognised, major 
comorbidity associated with RA and contrib-
utes to the increased mortality risk of patients 
with RA.7–11Gastro-oesophageal reflux disease 
(GORD) is a widely prevalent disorder of 
the GI tract. It manifests with major upper 
GI symptoms, heartburn and acid regurgi-
tation due to reflux of gastric contents into 
the oesophagus.12 A study from Japan docu-
mented a higher prevalence of GORD among 
patients with RA compared with the general 
population (24.6% vs 11.5%).13 A study from 
the USA showed that GORD was more likely 
among patients with RA aged <60 years.14 Anti-
rheumatic medications (particularly, non-ste-
roidal anti-inflammatory drugs (NSAIDs)) 
have been blamed for the increased burden 
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strengths and limitations of this study
 ► This study used a population-based dataset.
 ► The large sample size provided appropriate 
statistical power to detect real differences between 
the two groups.
 ► The dataset used lacks clinical information and 
therefore did not allow us to distinguish study 
patients according to the severity of their gastro-
oesophageal reflux disease or rheumatoid arthritis.
 ► As no standardised criteria were used to define 
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of GI diseases among patients with RA.15–17 An alternative 
hypothesis has been recently proposed that GI disorders 
may be part of the clinical spectrum and pathogenesis of 
RA disease.9 18
The link between GORD and RA may extend beyond 
shared pathogenic processes. As is well documented, 
both genetic (eg, heritability and family history3 19) 
and environmental factors (eg, smoking and low socio-
economic status or educational attainment20 21) are 
involved in the pathogenesis of RA.22 Recent studies have 
suggested a role of the microbiome in RA risk and its 
progression.23 24 Studies based on animal models suggest 
a prominent role of the gut microbiome in the progres-
sion of RA.23 Evidence for the immunological relevance 
of peptides from gut microbes was strengthened by their 
detection in synovial tissues and peripheral blood mono-
nuclear cells among patients with newly diagnosed RA.25 
As these evidences examined mainly on lower GI, none 
has attempted to investigate the potential role of upper 
GI tract microbiomes (eg, GORD) on RA development. 
Nevertheless, it would be plausible that chronic inflam-
mation resulting from the repeated acid reflux in GORD 
may cause mucosal damage and translocation of the 
microbiome from the gut into the circulation,26 27 GORD 
may therefore serve as a facilitating factor for RA patho-
genesis, a hypothesis that could be tested by looking for 
evidence that GORD predates RA and that GORD is asso-
ciated with disproportionately more new RA diagnoses 
than among persons without GORD. This study investi-
gates whether GORD is associated with increased risk of 




Sample patients were selected from the Taiwan Longi-
tudinal Health Insurance Database 2005 (LHID2005), 
hosted by the Taiwan National Health Research Institutes. 
Taiwan implemented its National Health Insurance (NHI) 
programme in 1995. The LHID2005 contains registration 
files and all medical care claims for 1 000 000 enrollees 
randomly selected from all enrollees (n=23.72 million) 
listed in the 2005 Registry of NHI Beneficiaries. The 
LHID2005 allows researchers to longitudinally track 
medical services provided to the selected enrollees since 
NHI inception in 1995.
This study was exempt from full review by the Insti-
tutional Review Board of Taipei Medical University 
(TMU-JIRB 201612025) since the LHID2005 consists of 
de-identified secondary data released without restriction 
to researchers for research purposes.
study sample
This nested case–control study included a study group and 
a comparison group. To select the study group, we first 
retrieved 21 395 patients who visited clinics or ambulatory 
care centres for the treatment of GORD (International 
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) code 530.11 or 530.81) between 
1 January 2002 and 21 December 2008. We excluded 
paediatric patients (<18 years of age, n=594) in order 
to limit the sample to the adult population. To improve 
the validity of the GORD diagnoses, we included only 
those patients who were diagnosed by either endoscopy 
or 24 hour pH monitoring, and additionally, received a 
proton-pump inhibitor prescription for more than 30 
days (n=13 977). We assigned the first date of the GORD 
diagnosis as the index date for study patients. Finally, we 
excluded 332 patients with GORD who had a diagnosis 
of RA (ICD-9-CM code 714.0) preceding the index date 
of the GORD diagnosis. The final study group included 
13 645 patients with GORD.
To select comparison patients from the remaining 
patients of the LHID2005 dataset, we first excluded 
patients with any claim showing a diagnosis of GORD 
since initiation of the NHI program in 1995 and all paedi-
atric patients. We used propensity score matching to select 
13 645 comparison patients (one for every study patient 
with GORD). The selected variables, age, sex, monthly 
income (NT$0~15 840, NT$15 841~25 000≥NT$25 001; 
average exchange rate in 2008, US$1.00≈New Taiwan 
(NT)$29), geographical location (Northern, Central, 
Southern and Eastern), urbanisation level of the patient’s 
residence, the year of the index date and medical comor-
bidities, were entered into a multivariable logistic regres-
sion model as predictors to calculate each patient’s 
expected probability of receiving a GORD diagnosis. Resi-
dential urbanisation level is classified by the Taiwanese 
National Health Research Institute into five levels (one 
being the most urbanised and five least urbanised). 
Medical comorbidities were identified using ICD-9-CM 
codes and included hyperlipidaemia (272.0–272.4), 
diabetes (250), hypertension (401–405), coronary heart 
disease (410–414 or 429.2), stroke (430–438) and obesity 
(278, 278.0, 278.00 or 278.01). The diagnosis of tobacco 
use disorder (305.1) in the claims data was used to iden-
tify severe current smokers. These comorbid conditions 
were included only if the condition occurred in an inpa-
tient claim or in two or more ambulatory care claims 
within 2 years before the index date.
For the study group, the year of the index date was the 
year in which they received their first-time diagnosis of 
GORD. To create the comparison group, comparison 
patients were selected based on matched propensity 
scores for receiving a GORD diagnosis. We then assigned 
their first healthcare use that occurred in the index year 
of the matched study patient as the index date for the 
comparison patient. All comparison patients’ prior claims 
were screened to ensure that none of them had a history 
of RA prior to their index date.
The study included 13 645 study patients and 13 645 
comparison patients. We tracked each patient’s claims 
over a 5-year period from their index date to identify those 
who subsequently received a diagnosis of RA (ICD-9-CM 
code 714.0). To enhance validity of the RA diagnosis, we 
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Table 1 Demographic and clinical characteristics of sampled patients (n=27 290)
Variable
Patients who received a diagnosis 
of GORD, n=13 645 Comparison patients n=13 645
p ValueTotal number Column % Total number Column %
Males 6490 47.6 6474 47.5 0.846
Age, mean (SD) 48.2±15.0 48.1±16.1 0.064
Urbanisation level
  1 (most) 4512 33.1 4430 32.5 0.780
  2 3852 28.2 3907 28.6
  3 1964 14.4 2011 14.7
  4 1827 13.4 1817 13.3
  5 (least) 1490 10.9 1480 10.9
Monthly income
  NT$0–15 840 4688 34.4 4782 35.0 0.204
  NT$15 841–25 000 4800 35.2 4837 35.5
  ≥NT$25 001 4157 30.5 4026 29.5
Geographical region
  Northern 6615 48.5 6707 49.1 0.168
  Central 4013 29.4 3827 28.0
  Southern 2724 20.0 2740 20.1
  Eastern 293 2.1 281 1.8
Hypertension 4218 30.9 4121 30.2 0.202
Diabetes 1922 14.1 1864 13.7 0.310
Tobacco use disorder 428 3.1 392 2.9 0.202
Hyperlipidaemia 4095 30.0 3976 29.1 0.114
Obesity 245 1.8 219 1.6 0.223
Stroke 1240 9.1 1165 8.5 0.109
Coronary heart disease 1483 10.9 1473 10.8 0.846
Number of ambulatory care visits 
within 1 year after index date
28.6±22.6 18.7±18.1 <0.001
Note: The average exchange rate in 2008 was US$1.00≈New Taiwan (NT)$29.
GORD, gastro-oesophageal reflux disease.
identified only those patients who showed a RA diagnosis 
in at least two distinct medical encounter claims.
statistical analysis
We used the SAS system for statistical analyses. We used 
Pearson’s Χ2 tests to examine differences between GORD 
patients and comparison patients on sociodemographic 
characteristics and medical comorbidities. We performed 
a log-rank test to examine the difference in 5-year RA-free 
survival between the two groups. We performed Cox 
proportional hazard regressions to calculate the HR and 
95% CI for the subsequent occurrence of RA over 5-year 
follow-up.
We verified that the data were consistent with the 
proportional hazards assumption by confirming that the 
survival curves for both strata (GORD and comparison 
patients) had hazard functions that were proportional 
over time. Finally, we censored patients who died or were 
lost to follow-up during the study (787 study patients 
(5.77% of patients with GORD) and 801 comparison 
patients (5.87% of the comparison group)). A signifi-
cance level of 0.05 was used.
results
Table 1 shows the sample demographic distribution 
stratified by the presence or absence of GORD. Because 
of propensity score matching, there was no significant 
difference in age, sex, monthly income, urbanisation 
level, geographic region and medical comorbidities 
between patients with GORD and comparison patients 
(all p>0.05). However, there was a significant difference 
in the number of ambulatory care visits within 1 year of 
the index date (p<0.001).
The incidence of RA during 5-year follow-up is 
presented in table 2. RA incidence was 2.81 (2.42–3.24) 
per 1000 person-years of observation among patients 
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Table 2 HRs for rheumatoid arthritis (RA) among sampled patients during the 5-year follow-up period
Presence of RA Total sample, n=27 290
Patients who received 





Yes, n (%) 242 (0.89) 186 (1.36) 56 (0.41)
Incidence rate per 1000 person-
years (95% CI)
1.82 (1.60 to 2.06) 2.81 (2.42 to 3.24) 0.84 (0.64 to 1.09)
HR (95% CI) – 3.35*** (2.48 to 4.52) 1.00
Adjusted HR* (95% CI) 2.84*** (2.09 to 3.85) 1.00
*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.

















Yes 50 0.77 21 0.32 136 1.90 35 0.49
Incidence rate per 
1000 person-years 
(95% CI)
1.58 (1.18 to 2.09) 0.68 (0.42 to 1.04) 3.93 (3.29 to 4.64) 0.98 (0.68 to 1.36)
HR (95% CI) 2.39*** (1.43 to 3.98) 1.00 3.95*** (2.72 to 5.74) 1.00
Adjusted HR* 
(95% CI)
2.00*** (1.18 to 3.37) 1.00 3.36*** (2.30 to 4.91)
*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.
with GORD and 0.84 (0.64–1.09) per 1000 person-years 
among comparison patients. The log-rank test showed 
that patients with GORD were more likely to be diagnosed 
with RA than comparison patients (p<0.001). Table 2 
also shows the Cox HRs for RA. The HR for RA among 
patients with GORD relative to comparison patients over 
5-year follow-up was 2.84 (95% CI 2.09 to 3.85) after 
censoring deaths and loss to follow-up and adjusting for 
the number of ambulatory care visits within 1 year of the 
index date. For the 242 sample patients who received an 
RA diagnosis during the follow-up, the mean gap between 
the index date and RA diagnosis was 756 days (SD 502 
days), being 839 and 481 days, respectively, for patients 
with and without GORD.
We conducted a stratified proportional hazard analysis, 
stratifying on sex (table 3). For females with GORD, the 
HR for RA was higher (adjusted HR 3.36, 95% CI 2.30 to 
4.91) than males (adjusted HR 2.00, 95% CI=1.18 to 3.37).
We used sensitivity analysis to assess the possible role 
of surveillance bias, which may increase the likelihood of 
chronically ill patients being subsequently diagnosed with 
other diseases due to their greater frequency of medical 
encounters than healthier patients. Patients with GORD 
may visit doctors more often than comparison patients 
and therefore have a greater chance of being diagnosed 
with RA, while those in the comparison group may disre-
gard mild symptoms and remain undetected for some 
time. Table 4 presents the results of sensitivity analysis. 
After excluding patients who were newly diagnosed with 
RA within 60 days following the index date and adjusting 
for the number of ambulatory care visits in the first year 
of follow-up, the adjusted HR was 2.81 (95% CI 2.06 to 
3.83), closely similar to the unadjusted HR.
dIscussIOn
To our knowledge, this study is the first to investigate the 
5-year risk of RA among patients with GORD. Propen-
sity score matching (using age, sex, monthly income, 
geographical location, residential urbanisation level, year 
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Table 4 HRs for rheumatoid arthritis (RA) among sampled patients during the 5-year follow-up period after excluding sampled 
patients who received an RA diagnosis within 60 days after the index date
Presence of RA Total sample, n=27 279
Patients who received 





Yes, n (%) 231 (0.85) 177 (1.30) 54 (0.40)
HR (95% CI) – 3.31*** (2.43 to 4.49) 1.00
Adjusted HR* (95% CI) 2.81*** (2.06 to 3.83) 1.00
*Adjustments were made for the number of ambulatory care visits within 1 year after the index date.
The HR was calculated by a Cox proportional hazard regression.
***p<0.01.
GORD, gastro-oesophageal reflux disease.
of the index date and medical comorbidities) was done 
to select comparison patients without GORD in order to 
mitigate selection bias. During the 5-year follow-up, we 
documented RA incidence per 1000 person-years of 2.81 
for patients with GORD and 0.84 for comparison patients. 
We also observed that after mitigating surveillance bias, 
GORD was independently associated with 2.84-fold higher 
risk of RA during 5-year follow-up, after adjusting for the 
number of ambulatory care visits within 1 year of the 
index date. Our findings may support previously docu-
mented animal model evidence that implicated a patho-
genetic role of GORD in RA risk and its progression.
Upper GI diseases are major comorbid medical condi-
tions contributing to the impaired quality of life and 
increased mortality risk experienced by patients with 
RA.7-11
A Japanese study specifically linked RA with GORD, 
a common GI condition among patients with RA. The 
authors reported that the prevalence of GORD was 
significantly higher among patients with RA, compared 
to the general population.13 GI disease has been, thus far, 
considered an adverse effect of RA treatment, particularly 
NSAIDs.15 16 28 29 No study has examined whether GORD is 
simply a comorbid illness occurring after the RA diagnosis 
due to treatment. In recent years, it has been suggested 
that GORD may be implicated at a much earlier stage in 
shaping the disease risk, in light of increasing research 
on the role of environmental factors in the pathogenesis 
of RA (eg, microbiome effects23 24). Our study presents 
epidemiological evidence that GORD is associated with a 
subsequent RA diagnosis over 5-year follow-up. Given that 
GORD predated the RA diagnosis by a substantial period 
of time (more than 2 years in average), it appears unlikely 
that GORD was merely an early manifestation of under-
lying, asymptomatic RA pathology.
In additional analysis that classified the sample by sex, 
we observed that the RA increased RA risk of patients 
with GORD relative to comparison patients is heightened 
among females (males OR 2.00, 95% CI 1.18 to 3.37; 
females OR 3.36, 95% CI 2.30 to 4.91). The magnitude of 
difference between the sexes is consistent with the known 
sex bias of RA incidence; approximately 70% of patients 
with RA are women.30 No statistically significant findings 
were observed on stratification by age.
How the RA risk is intensified among patients with 
GORD has not been articulated. Tentative evidence, 
though mainly focusing on lower GI, suggests the possi-
bility that the microbiome may play a role in many auto-
immune diseases, including RA.23 24 Clinical studies and 
laboratory research have investigated various factors 
in the pathogenesis of RA, including environmental 
factors, genetic factors and inflammatory pathways. One 
currently prevailing hypothesis is that specific organisms 
in the mouth or gut microbiota may influence mucosal 
and systemic immune responses affecting the joints in 
patients with RA.31–33 Stool samples from patients with 
recent-onset RA, compared with patients with chronic 
RA, psoriatic arthritis or healthy individuals, show that 
Prevotella copri in the gut microbiota is overmagnified.34 
While dysbiosis is documented in patients with RA,35 a 
recent study in mice confirmed that dysbiosis contributes 
to arthritis development through activation of autoreac-
tive T cells in the intestines.36 Alterations in microbial 
populations in oral, salivary and other GI sites that were 
associated with C-reactive protein and autoantibodies 
against citrullinated peptides status and were also iden-
tified in human patients.37 Further, by liquid chromatog-
raphy tandem mass spectrometry, Pianta et al attempted 
to examine whether overmagnification of P. copri in the 
gut of human patients may alter immune cell functions 
at both mucosal and systemic sites, contributing to the 
pathogenesis of RA disease.25 They found that among 
42% of patients with RA, Th1 responses could be stim-
ulated in vivo by an human leucocyte antigen-antigen D 
related-presented peptide stemming from a P. copri 27-kD 
protein (Pc-p27). P. copri provoked differential antibody 
responses to the whole organism or this specific protein 
in a considerable fraction of patients with RA. As this 
evidence on lower GI revealed the immunological rele-
vance of the microbiota in the pathogenesis of RA, none 
has attempted to examine the role of upper GI illnesses, 
such as GORD in our study. How the occurrence of GORD 
may be linked with RA remains unknown. But presum-
ably, GORD, a chronic oesophageal injury that occurs due 
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to intermittent, abnormal reflux of gastric contents into 
the oesophagus, may damage the oesophageal mucosa.38 
Bacteria may then be translocated from the gut to the 
bloodstream and induce immune responses.26 Bacterial 
translocation, defined as the movement of viable bacteria 
from the gastrointestinal tract to extraintestinal locations 
such as the bloodstream, may be promoted through three 
mechanisms of: (a) intestinal bacterial overgrowth, (b) 
augmented permeability of the intestinal mucosal barrier 
and (c) deficits in host immune defences.26 27 GORD may, 
therefore, be associated with a subsequently increased RA 
risk, as observed in our epidemiological study. The patho-
biological pathways underlying these observations remain 
unknown and should be explored in future studies.
Our findings have important clinical and public health 
implications for managing GORD. Typically, patients with 
RA exhibit tender and swollen joints of recent onset, 
morning joint stiffness, and abnormal laboratory find-
ings such as elevated blood levels of C-reactive protein or 
erythrocyte sedimentation rates. However, none of these 
features are specific to RA, which impedes early diagnosis 
in many patients. Given that early diagnosis and prompt 
treatment of RA is emphasised,1 the treating medical 
team, if aware of the possible pathogenic link, may be 
able to arrive at the diagnosis sooner and initiate appro-
priate treatment.
A unique strength of this study was the use of a popula-
tion-based dataset, which allowed us to track all cases of 
GORD and RA during the study period. Moreover, the 
large sample size provided adequate statistical power to 
detect differences between the two groups.
Despite the strengths, the findings should be inter-
preted with caution due to certain limitations. First, an 
inherent limitation of a claims dataset is that only patients 
who sought medical treatment for GORD and RA were 
represented in this study. It is unlikely that incident cases 
of RA were missed because of the joint swelling, pain and 
discomfort that significantly impacts daily functioning, 
causing patients to seek medical care. Another potential 
source of bias is diagnostic misclassification of GORD 
or RA. In the absence of standardised criteria to define 
cases, GORD is particularly liable to be underdiagnosed 
due to its wide range and severity of manifestations and 
subjective perceptions of patients some of whom may not 
seek treatment.39 Such misclassification of GORD status 
would result in more undiagnosed patients with GORD 
among the comparison group and would potentially bias 
our results towards the null. Plausibly, therefore, the 
actual hazard of RA among patients with GORD may be 
higher than the observed HR in our study.
Second, the claims dataset lacks clinical information 
and did not allow us to distinguish study patients by 
the severity of GORD or RA. Third, there is no data on 
personal history such as family history of RA, body mass 
index, history of previous infections, exposure to air 
pollution and insecticides and occupational exposure to 
mineral oil or silica, which may contribute to RA.1 Given 
that smoking is an important risk factor for RA,21 40 the 
diagnosis of tobacco use disorder in the claims data was 
used to account for severe smoking behaviours, while 
leaving less intense smoking unaccounted for in the anal-
ysis. Another unavoidable confounder in retrospective 
studies is that patients with arthralgia or joint symptoms 
may consume more NSAIDS which directly increases the 
risk of GORD. Information on the prior existence of such 
conditions and on NSAID consumption or other relevant 
medications is not available in the dataset. Therefore, 
the current study design does not permit an unequivocal 
inference of a causal relationship between GORD and 
RA. Finally, the generalisability of our study findings may 
be limited to ethnic Chinese populations. Future studies 
will need to include other ethnic groups for evaluation.
Our findings extend the significance and implications of 
previously reported evidence regarding comorbid GORD 
among RA. It offers evidence that GORD, a common GI 
disease, is associated with increased risk of subsequent 
RA occurrence, using a large, population-based, national 
dataset. Although our exploratory study offers epidemi-
ological evidence of an association using a retrospective 
case–control approach, replication of the finding in 
other settings is required, as well as studies to better char-
acterise the link and verify the directionality and causal 
link, if any. Biomedical research is essential to elucidate 
the underlying pathways connecting GORD with RA to 
interpret the clinical significance of these epidemiolog-
ical findings.
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